

**MALARIA MEETING: PRELIMINARY AGENDA**  
**“ASMQ IN LATIN AMERICA: SUCCESSES AND CHALLENGES”**  
**When: 1st December 2011, 8h30 to 13h00**  
**Where: Rio de Janeiro, Hotel Othon Palace, Sala São Conrado**

**RAPORTEURS**

- Winnie Hagemeyer
- Luciana Gonçalves
- Daniel Mechali

**BACKGROUND**

Malaria has been one of the priority diseases included in DNDi’s portfolio since the creation of the organization. Within the multi-partner FACT (Fixed-Dose, Artesunate-Based Combination Therapies) Consortium created by DNDi and the UNICEF-UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases (TDR), two new Artesunate- based : fixed-dose combination, ASAQ (Artesunate-amodiaquine), developed in partnership with Sanofi-Aventis and ASMQ (Artesunate-mefloquine) developed in partnership with Farmanguinhos/Fiocruz were successfully launched respectively in 2007 and 2008, so as to address a public health need for user friendly, co-formulated drug regimens that improve patient compliance and dosing accuracy, and therefore may contribute for better efficacy and control of the development of resistance to ACTs.

Today, ASAQ is registered in 30 sub-Saharan countries and India and more than 80 million treatments have been distributed by end 2010. Moreover, technology transfer to African industry partner is in preparation.

In April 2009, the Brazilian Government completed the first public order of ASMQ to Farmanguinhos and, in 2010, ASMQ was included in the Practical Guideline for malaria treatment in Brazil, published by the MOH, as one of the two treatment recommendations, together with the fixed-dose combination artemeter+lumefantrine, for uncomplicated *Plasmodium falciparum* malaria<sup>1</sup>. ASMQ has also been included in the 2010 Brazilian National List of Essential Drugs (RENAME). Also, technology transfer has been successfully achieved to the Indian manufacturer, CIPLA, in order to facilitate its future availability in Southeast Asia, and a registration is currently under evaluation for WHO pre-qualification.

With these two FACTs successfully delivered, DNDi does not plan to be involved in the development of further anti-malarial agents and will conclude its malaria activities by 2014, in order to maintain full commitment to kinetoplastid diseases and expand its portfolio to new neglected diseases.

This gathering of our partners for the first time in Latin America is an opportunity to learn. To make a balance of current achievements and future challenges to address needs of patients in the Latin American region. It is also an opportunity to suggest recommendations and ways to move forward.

**Main objective of the session/meeting**

- To update on current and future ASMQ FDC achievements and address current challenges in Brazil and the region

<sup>1</sup> Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Guia prático de tratamento da malária no Brasil / Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância Epidemiológica. – Brasília : Ministério da Saúde, 2010

### Sub-objectives

- To assess opportunities to expand the use in the region for Malaria Falciparum
- To review limitations and barriers to access
- To review lessons learnt
- To address possible avenues in other types of Malaria and the use of anti-malarial drugs in other regions

TIME	AGENDA	Chair: Jean-René Kiechel
<b>8h30-9h00</b>	<b>Coffee and Welcome</b>	
9h00-9h10	Welcoming remarks	Vice-President FIOCRUZ Claude Pirmez
9h10-09h25	ASMQ FDC for LA and Asia Product presentation and current status	Graciela Diap
9h25-9h45	Challenges and opportunities in Latin America	Eric Stobbaerts
<b>09h45-10h15</b>	<b>Coffee break</b>	
10h15-10h30	WWARN: World Wide Anti-malaria Resistance Network	Carol Sibley
10h30-12h30	Round Table : "Overcoming barriers towards better ASMQ access to patients"  <u>Discussants:</u> <ul style="list-style-type: none"> <li>• Ana Carolina Santelli, Brazil Malaria Control Programme</li> <li>• Christophe Rerat, PAHO</li> <li>• David Mc Gibney, MMV</li> <li>• Hayne Felipe, FARMANGUINHOS</li> <li>• Jaime Chang, USAID/RAVREDA (video-conference)</li> </ul> <u>Special Guests:</u> <ul style="list-style-type: none"> <li>• Nelson Pizzo, Programme in Venezuela</li> </ul>	Chair: Jean-René Kiechel
12h30-13h00	Concluding Remarks	Jean-René Kiechel
<b>13h00-14h00</b>	<b>Lunch Buffet</b>	

### List of Participants

Name	Surname	Function / affiliation
Hayne Felipe	da Silva	Director, Farmanguinhos, Brazil
Jean René	Kiechel	DNDi - Geneva
Christophe	Rerat	PAHO
Jaime	Chang	AMI/USAID
André	Daher	DNDi - Latin America
Graciela	Diap	DNDi - Geneva
Daniel	Mechali	DNDi - Latin America
Eric	Stobbaerts	DNDi - Latin America
Luciana	Gonçalves	DNDi - Latin America
Erico	Daemon	Farmanguinhos
Jorge	Mendonça	Farmanguinhos
Márcia Rawlinson	Rodrigues	Farmanguinhos
Maria Cristina	Milen	Farmanguinhos
Shirley	Trajano	Farmanguinhos
Claude	Pirmez	Fiocruz - Vice-President
José Maria	Souza	Instituto Evandro Chagas
Ana Carolina	Santelli	National Malaria Programme, Brazil
Nunzio Nelson	Pizzo	Dirección General de Salud Ambiental MPPS; Programa de Malaria, Venezuela
Mayira	Sojo-Milano	PAHO - Brasilia
David	McGibney	Medicines for Malaria Venture (MMV)
Carol	Sibley	WWARN
Winnie	Hagemeyer	Rapporteur